Orum’s Cell-Penetrating Antibody Platform
Full-length IgG antibodies that specifically bind to a target molecule with high affinity have been extensively developed as research tools, as well as for diagnostic and therapeutic purposes. However, these antibodies are designed primarily to target proteins expressed on the cell-surface or on some secreted proteins. This is because antibodies usually cannot cross intact cellular or subcellular membranes in living cells due to their large size and hydrophilicity.
At Orum, we developed cell-penetrating antibodies, which can access the cytosol of living cells following receptor-mediated endocytosis. This unique capability will enable next-generation therapeutic antibodies that directly target cytosolic proteins, which are associated with many untreatable or difficult-to-treat human diseases such as cancer or rare diseases.
In principle, we can engineer various therapeutic antibodies with the ability to enter the cytosol.
Our fully human antibodies do not require chemical conjugation or formulation for delivery. Therefore, the manufacturing procedures we would use are similar to those used for any therapeutic monoclonal antibody.
Cell specific targeting
Our antibodies can be engineered to specifically bind different cell-surface receptors to enhance targeting to specific tissues.